MedTrace Logo

Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma

NCT00425061 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2015-01-14

Study results available
· View outcomes & findings →

Summary

Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with persistent asthma.

Conditions

Interventions

BIOLOGICAL

IMA-638

SC Injection, 12 weeks

BIOLOGICAL

IMA-638

SC Injection, 12 weeks

OTHER

placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00425061 on ClinicalTrials.gov